OBJECTIVES Lifelong immunoglobulin G (IgG) replacement is the standard therapy for patients with primary antibody deficiencies. It can be administered either intravenously (IVIg) by health care providers in hospital or subcutaneously (SCIg) by patients at home. However, self-administration requires patients' education and support over long term to ensure proper adherence and optimal efficacy and safety. Every patient who switches to SCIg is proposed by the Policlinique Médicale Universitaire (Lausanne, Switzerland) a drug therapy management program with a nurse and a community pharmacist including training, coaching and follow-up. The aim of the study was to evaluate if switching to SCIg at home including the management program was cost-effective compared to IVIg at hospital. METHODS Assuming that both therapies provide similar efficacy, a 3-years cost-minimization analysis based on a simulation model was performed from a societal perspective. Health care costs (IgG, time of professionals, infusion pumps and disposables) were derived from administrative data. Transport and losses of productivity were estimated. One-way sensitivity analyses were performed. RESULTS Under base case assumptions, SCIg at home was estimated at 34960 CHF per patient the first year and 30 030 CHF in subsequent years against 34 170 CHF per year for IVIg. The total savings for a switch to SCIg at home with the program was 7490 CHF per patient over 3 years. Results were relatively sensible to the assumptions. CONCLUSIONS Home-based SCIg therapy including an interprofessional therapy management program may be an effective and efficient alternative to hospital for patients with primary antibody deficiencies. Additional costs from purchase of equipment and management program in the first year were offset by hospital costs avoided in short term. Additional studies are ongoing to analyse the retention in the therapy in medium term and the impact on quality of life.